Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

10.72
-0.3400-3.07%
Post-market: 10.70-0.0200-0.19%19:30 EDT
Volume:1.01M
Turnover:10.87M
Market Cap:707.66M
PE:-2.85
High:11.16
Open:11.14
Low:10.49
Close:11.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:1.11
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:9.86
PE(LYR):-2.85

Loading ...

Regenxbio Inc - Expects Cash Position to Fund Operations Into Early 2027

THOMSON REUTERS
·
May 14

Regenxbio's muscle disorder therapy meets main goal in late-stage study

Reuters
·
May 14

Regenxbio Inc - Rgx-202 Shows Favorable Safety Profile With >80% Full Capsid Purity

THOMSON REUTERS
·
May 14

Regenxbio Inc - Plans Potential Commercial Launch of Rgx-202 in 2027

THOMSON REUTERS
·
May 14

Regenxbio Inc - Two Serious Adverse Events Reported, Both Resolved Without Sequelae

THOMSON REUTERS
·
May 14

Regenxbio Inc - Phase Iii Study Achieves Primary Endpoint With 93% of Patients Above 10% Microdystrophin Expression

THOMSON REUTERS
·
May 14

Regenxbio Announces Positive Topline Results From Pivotal Phase Iii Affinity Duchenne® Study of Rgx-202

THOMSON REUTERS
·
May 14

Regenxbio Inc - Rgx-202 Shows Significant Correlation Between Microdystrophin Expression and Functional Improvement

THOMSON REUTERS
·
May 14

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
May 14

Regenxbio CMO Steve Pakola disposes of shares worth $168,704.18

Reuters
·
May 14

Regenxbio Inc expected to post a loss of $1.34 a share - Earnings Preview

Reuters
·
May 12

Regenxbio Inc expected to post a loss of $1.34 a share - Earnings Preview

Reuters
·
May 08

Regenxbio to present at ASGCT annual meeting

Reuters
·
May 07

Regenxbio Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

THOMSON REUTERS
·
May 07

Regenxbio updates financial calendar with first-quarter results release, webcast

Reuters
·
May 06

Regenxbio announces annual shareholder meeting, releases preliminary proxy statement

Reuters
·
Apr 04

Regenxbio shares drop 17.8% due to RGX-111 securities class action; lead plaintiff deadline set for April 14, 2026

Reuters
·
Mar 26

Shareholders Sue RGNX Over Gene Therapy Study Claims

TIPRANKS
·
Mar 24

BRIEF-Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing

Reuters
·
Mar 21

Regenxbio Inc - to Continue to Pay GSK Amounts Received From Sublicensees Pursuant to Existing Sublicense Agreements - SEC Filing

THOMSON REUTERS
·
Mar 21